On July 17, Japan’s Cabinet adopted the 2020 Basic Policy on Economic and Fiscal Management and Reform (honebuto). Its initial text suggested the government’s position to carry out its first off-year drug price revision next April as well as its…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AstraZeneca Aims to Deliver100 Million Doses of Coronavirus Vaccine to Japan: CEO
July 21, 2020
-
BUSINESS National CV Center Spin-Off Developing Oligonucleotide Therapy for Dyslipidemia, Eyes 1st Trial in FY2022
July 20, 2020
-
REGULATORY 2020 Policy Blueprint Restresses Efforts on COVID-19 Meds/Vaccines; Drug Price Survey Up for Discussion on July 22
July 20, 2020
-
REGULATORY Japan Govt Adopts 2020 Honebuto Policy, Drug Price Survey to Be Conducted This Autumn
July 17, 2020
-
BUSINESS Kyowa Pharma Expanding Focus Beyond Drugs, Eyes New Diagnostic/Treatment Options in CNS
July 17, 2020
-
REGULATORY Japan Govt to Push Ahead with Off-Year Survey, Considering COVID-19 Impact to Decide on Re-Pricing
July 16, 2020
-
REGULATORY Japan Govt to Tweak Honebuto Text for Off-Year Re-Pricing, but Still Holds to Original Plan
July 15, 2020
-
BUSINESS Shionogi, Ping An to Set Up JV in August, Make It a Hub for China/Asia Biz
July 14, 2020
-
BUSINESS Takeda Looks to Derive 70%-Plus of Japan Sales from 5 Focus Areas by FY2025, Revamp HR Systems
July 13, 2020
-
ACADEMIA Avigan Fails to Hit Statistical Significance in COVID-19 Trial: Fujita Health Univ.
July 13, 2020
-
COMMENTARY Diabetes Market Regaining Momentum with New Launches; First Oral GLP-1 a Game Changer?
July 13, 2020
-
BUSINESS Bayer Revving Up Cell Therapy Drive with First Focus on Parkinson’s, Japan Biz Also Eyed: R&D Chief
July 10, 2020
-
REGULATORY LDP Lawmakers Irked as Govt Stands Fast on Off-Year Re-Pricing/Survey Plan; Honebuto Text Tweak Unclear
July 10, 2020
-
REGULATORY Original Plan Remains Unchanged for Off-Year Drug Re-Pricing, Survey: Minister
July 9, 2020
-
BUSINESS Aducanumab Filing Completed in US; Talks with Japan/EU Regulators Ongoing
July 9, 2020
-
ORGANIZATION Mobile Pharmacy Van Set in Motion as Kumamoto Downpour Hits Local Stores, Some Wholesalers
July 8, 2020
-
ORGANIZATION Wholesaler Group Makes Emergency Plea against Off-Year Drug Price Survey
July 7, 2020
-
BUSINESS Ono to Fight Prof. Honjo’s Lawsuit over Opdivo Royalties
July 7, 2020
-
REGULATORY Japan Govt Likely to Stick to 2020 Off-Year Drug Re-Pricing Plan in Honebuto Paper
July 6, 2020
-
BUSINESS Maviret Shrivels, but AbbVie Japan in “Growth Mode” with Oncology, Immunology Drivers: Chief
July 3, 2020
ページ
Since last year, Japan has seen a number of stock-outs and shortages of generic drugs attributable to API supply disruptions…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In a change striking to the very core of the traditional Japanese salaryman, “We are seeing the coronavirus ushering in a new way of working… and I think it’s about time,” says Ivan Tselichtchev, Professor of Economics at the Niigata…